Here are a few excerpts from the 2 hour 45 minute Joe Rogan interview with Dr. Peter McCullough:
ROGAN: "Why do you think hydroxychloroquine was demonized? Why do you think that it was, especially so early on in Australia? It can’t be universal incompetence across the board. So one of the things that’s interesting about Ivermectin is it’s not demonized worldwide. It’s distributed widely in other countries and it’s shown some effectiveness."
McCULLOUGH: "Absolutely. Ivermectin now is first line in Japan. It’s attributed to crushing the curves in Mexico. In Peru absolutely crushed the curves in India. We’ve been in close communication with them. Ivermectin is an interesting drug and I know you’ve reviewed it in depth on this show, so I’ll leave it to experts like Dr. Kory and others there, but I use it every day in my practice I have no problems with Ivermectin. It is safe and effective.
It’s been a Nobel Prize awarded in 2015 for Ivermectin. But hydroxychloroquine, I think worldwide is still the leading drug used to treat Covid at 19. Just because of its availability, it’s known dosing about the interesting thing between Hydroxychloroquine and Ivermectin is Ivermectin has a range inpatient and outpatient and has a bigger effect size. In general. Both of them have are still lacking the 20,000 to 40,000 patient clinical trial as a singular drug. Dr. McCullough And I honestly don’t think we’ll ever get there. By the way, we’re in the multi drug space, so we’re never going to go back to single drugs. We’re in the multi drug environment. So there are no large multi drug trials even planned at this point in time. So we’re left with where we are signals to benefit acceptable safety.
But to finish the thought, Ivermectin has a range of effect sizes that are gratifying inpatient and outpatient diminishing efficacy later. Hydroxychloroquine has really no support on the inpatient side outside the big Henry Ford study. So Hydroxy is largely an outpatient drug. The advantages of hydroxychloroquine are stable dosing, 200 milligrams twice a day. We either go 5, 10, or 30 days. We even have protocols where it’s been done that way. Ivermectin the dosing is 200, 400 or 600 micrograms per kilogram, and the dose intervals still are yet to be standardized or worked out. So it’s interesting. So you see an entire range of doses of Ivermectin, even clinically today.
I don’t know. Do I go five days? Do I do ten days? Do I do every other day? I don’t know.
We use the drugs and I’m comfortable with that. I can live with ambiguity in the setting of a crisis. The point is, these are very safe and effective drugs. They’re useful drugs. I saw a trend.
You’ve asked me three times, so I’m going to answer it. I saw a trend starting in April, May and June where it became clear that anything we were doing to try to help patients with early treatment was receiving a chill and the chill was coming through academic institutions through the medical literature. I think the capper was in June when there was a fraudulent paper published in Lancet on Hydroxychloroquine between Harvard and a company called Surgisphere. And this never happens. Lancet is like the New England Journal Medicine of the World.
I’m the editor of a major Journal. I run a Journal. I know what it takes. There are editors, associate Editors, reviewers. There is pinpoint accuracy. We check references we check plagiarism. Believe me, it’s a tight world out there. They basically published a fraudulent paper on hydroxychloroquine in Lancet in 2020 around June, and they let it hang up there for two weeks stating that hydroxychloroquine was associated with harm when used in patients with COVID-19."
"I talked to Scott Atlas. I presented with him a couple of weeks ago, and I had dinner with Scott. He was on the inside. He worked side by side with these people for months. I said, Scott, what is going on? Scott goes, I did what Peter McCullough would do.
I showed up every day with the data. I analyzed things. I had the updates on what’s going on with the pandemic. Scott was focused on mass contagion control in schools, but he’s an academic. He’s at Stanford Hoover Institute. I said, what about the other people on the task force? What about the head of the NIAD? What about the CDC director? He goes, they showed up with nothing.
I said, You’ve got to be kidding me. They’re not analyzing any data? He goes, “Have you ever seen them come on TV and analyze any studies?” I said, no. He thinks that this is a crisis of academic incompetence."
McCULLOUGH: "As a doctor, all I can tell you is the medical literature, as we are seeing it come about. There was, once the discovery that the spike protein on the virus, the discovery in the medical literature. Now that discovery we learned actually occurred years before. This was amenable to neutralization with vaccine induced antibodies.
Once that became abundantly clear in the literature, there appeared to be almost a lockstep developed where people said that’s it. That’s the solution. We’re going to vaccinate our way out of this problem. We don’t even need to worry about how to treat the problem. We don’t need to hear about drugs to treat the problem. And the enthusiasm and the hubris for vaccination spread across academic medical centers all over the country."
ROGAN: "But what about the people that were currently sick and they were still waiting for the roll out of the vaccine. So if you’re talking about August, the vaccine wasn’t rolling out for another four months. And that’s just for elderly people."
McCULLOUGH: I published an op Ed in August of 2020 in the Hill, a Republican Journal for Washington people and others in those circles. And the title of the oped was The Great Gamble of the Covid 19 Vaccine Development Program. And what I saw is I saw a total shift on everything for the vaccines. Do you know major clinical trials of hydroxychloroquine were dropped, Ivermectin things were dropped.
We had programs for Favipiravir, the Canadians had a big thrust for Favipiravir dropped. I was the principal investigator overall for the Ramatraban program. That was a Japanese product. It was an anti coagulant antihistamine look very promising. We had great preliminary data.
We had a bear that was going to give us all the doses we needed to treat America. I was on calls between the NIH and the FDA. Back and forth, back and forth. I couldn’t get any traction in the summer of 2020. It was obvious.
In fact, I remember one of the operation Warp speed officers telling me, listen, sorry. We have everything organized for the current program. I was also the assistant. I was kind of second in charge of the Modulon program, which was a cellular based vaccine that was a vaccine similar to the BCG vaccine, which is given for tuberculosis. We had noticed that regions that were vaccinating for tuberculosis like Haiti and countries in Central Africa, very little Covid.
And so we had the idea. We got a Dutch manufacturer to actually make this cellular based vaccine. We’re going to vaccinate healthcare workers. Same thing. Endless proposals between NIH and FDA got nowhere because it looked like it was already pre decided that the current set of genetic vaccines were going to move forward. There wasn’t going to be any discussion on early treatment. I thought it was a gamble. I was faced with more and more of my patients getting sick with Covid-19 and what I told people all over. I said, listen, I can’t let the virus slaughter my patients. I’m not going to do it.
I said, there’s got to be something I could do. Early on. I used hydroxychoroquine. Other drugs in combination, Pierre Kory, I give him great credit. His first contribution is actually steroids in the use of COVID-19. So we started using steroids. Once it was shown to us, we added steroids. The data started coming out anticoagulants, and that’s how I put it together. I tell you, Joe, every single one of my high risk patients I’ve always treated to prevent hospitalization and death.
Of the 800,000 deaths that we are right now, I can tell you to a one they’ve received either no or inadequate early treatment. Go look in a table of baseline characteristics of hospitalized patients with COVID-19 and look at what they received before they came to the hospital..."
ROGAN: "All of them?"
McCULLOUGH: Go look in a table of baseline characteristics of hospitalized patients with COVID-19 and look at what they received before they came to the hospital. Zilch." 13 December 2021.Transcript in full...
No comments:
Post a Comment